Literature DB >> 7743664

IL-4 mRNA expression by peritoneal cells during episodes of peritonitis in patients on continuous ambulatory peritoneal dialysis.

C J Watson1, J J Finlay-Jones, P J McDonald, P H Hart.   

Abstract

Peritoneal cells were isolated from dialysates drained from nine patients on continuous ambulatory peritoneal dialysis (CAPD) during episodes of peritonitis. Levels of expression of mRNA for the regulatory cytokines, interferon-gamma (IFN-gamma) and IL-4, were investigated daily, where possible, during the first 5 days of peritonitis. Cytokine mRNA levels were compared with those of peripheral blood mononuclear cells (PBMC) stimulated in vitro with phorbol 12-myristate 13-acetate (PMA) plus phytohaemagglutinin (PHA). Peritoneal cells expressed low levels of IFN-gamma mRNA; for four of nine patients, IL-4 mRNA levels greater than those expressed by stimulated PBMC were detected. There was no pattern of cytokine mRNA expression associated with the types of organisms detected in dialysates at initiation of peritonitis. However, in contrast to those patients with a transient, resolving peritonitis, significant IL-4 mRNA expression was detected in cells isolated early in the episodes of peritonitis in patients who suffered recurrent peritonitis within 30 days of the initial peritonitis episode. These results suggest an association between early IL-4 mRNA expression and susceptibility to further infections. The known anti-inflammatory effects of IL-4 may explain this association.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7743664      PMCID: PMC1534325          DOI: 10.1111/j.1365-2249.1995.tb03662.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

Review 1.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.

Authors:  T R Mosmann; R L Coffman
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

2.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

3.  Establishment of an immature mast cell line from a patient with mast cell leukemia.

Authors:  J H Butterfield; D Weiler; G Dewald; G J Gleich
Journal:  Leuk Res       Date:  1988       Impact factor: 3.156

4.  Differential CD4 T cell activation in measles.

Authors:  D E Griffin; B J Ward
Journal:  J Infect Dis       Date:  1993-08       Impact factor: 5.226

5.  Inflammatory fluids regulate TNF-alpha, but not IL-1 beta, production by human peritoneal macrophages. A study of patients on continuous ambulatory peritoneal dialysis with peritonitis.

Authors:  P H Hart; C A Jones; J J Finlay-Jones
Journal:  J Leukoc Biol       Date:  1993-03       Impact factor: 4.962

Review 6.  T-cell and cytokine responses in leishmaniasis.

Authors:  S G Reed; P Scott
Journal:  Curr Opin Immunol       Date:  1993-08       Impact factor: 7.486

7.  Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages.

Authors:  C S Hsieh; S E Macatonia; C S Tripp; S F Wolf; A O'Garra; K M Murphy
Journal:  Science       Date:  1993-04-23       Impact factor: 47.728

8.  Analysis of the causative pathogens in uncomplicated CAPD-associated peritonitis: duration of therapy, relapses, and prognosis.

Authors:  T A Golper; A I Hartstein
Journal:  Am J Kidney Dis       Date:  1986-02       Impact factor: 8.860

9.  Changes in cytokine production after measles virus vaccination: predominant production of IL-4 suggests induction of a Th2 response.

Authors:  B J Ward; D E Griffin
Journal:  Clin Immunol Immunopathol       Date:  1993-05

10.  Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets.

Authors:  F P Heinzel; M D Sadick; B J Holaday; R L Coffman; R M Locksley
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.